check_circleStudy Completed

Prostatic Neoplasms

Bayer Identifier:

15354

ClinicalTrials.gov Identifier:

NCT01565746

EudraCT Number:

Not Available

EU CT Number:

Not Available
Safety, biodistribution, radiation dosimetry and pharmacokinetics study of BAY88-8223 in Japanese patients

Trial purpose

This is an uncontrolled, open-label, non-randomized Phase I study to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of a single dose of BAY88-8223 in Japanese patients with castration-resistant prostate cancer and bone metastases.

Key Participants Requirements

Sex

Male

Age

20 - N/A
  • - Male ≥ 20 years of age
    - Histologically or cytologically confirmed adenocarcinoma of the prostate
    - Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks
    - Patients who has failed initial hormonal therapy using either an orchiectomy or a Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks
    - Progressive castration resistant metastatic disease
    - Castrate level of testosterone (<50 ng/dL), treatment to maintain castrate levels of testosterone must be continued
  • - Has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration.
    - Has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy
    - Has received prior hemibody external radiotherapy
    - Has a need for immediate external radiotherapy
    - Has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug
    - When receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug

Trial summary

Enrollment Goal
19
Trial Dates
March 2012 - April 2016
Phase
Phase 1
Could I Receive a placebo
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Kashiwa, 277-8577, Japan
Completed
Yokohama, 236-0004, Japan
Completed
Osakasayama, 589-8511, Japan

Primary Outcome

  • Number of participants with Critical toxicities
    Critical toxicities (using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0) will be defined as the occurrence of one or more of the following drug-related toxicities: 1) ≥Grade 3 non-hematologic toxicity, 2) Grade 3 neutropenia with fever, 3) Grade 4 neutropenia that failed to recover to grade 2 or less after treatment with Granulocyte colony-stimulating factor (GCSF) within 2 weeks, 4) Grade 4 thrombocytopenia
    date_rangeTime Frame:
    Up to day 28
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum drug concentration in blood after single dose administration (Cmax) of BAY88-8223 for blood samples
    date_rangeTime Frame:
    up to 72 hours
    enhanced_encryption
    Safety Issue:
    No
  • Area under the concentration - time curve (AUC) of BAY88-8223 for blood samples
    date_rangeTime Frame:
    up to 72 hours
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Changes in prostate specific antigen (PSA)
    date_rangeTime Frame:
    baseline, up to 12 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Overall Survival
    date_rangeTime Frame:
    Up to 36 months
    enhanced_encryption
    Safety Issue:
    No

Trial design

Uncontrolled, open-label, non-randomized Phase I study to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of a single dose of BAY88-8223 in Japanese patients with castration-resistant prostate cancer and bone metastases
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
3

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.